1-13 of 13
Jean-Pierre Delord
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2762–2770.
https://doi.org/10.1158/1078-0432.CCR-22-0696
Published: 01 July 2022
View article titled, Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Open the PDF for Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study in another window
Journal Articles

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John Powderly, Lauren C. Harshman, Paul Conkling, Jean-Pierre Delord, Michael Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, III, Sanjeev Mariathasan, Carol O'Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3360–3369.
https://doi.org/10.1158/1078-0432.CCR-20-1981
Published: 15 June 2021
View article titled, Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Open the PDF for Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Anne Montfort, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pagès, Pascale Olivier, Maha Ayyoub, Muriel Mounier, Amélie Lusque, Stéphanie Brayer, Jean-Pierre Delord, Nathalie Andrieu-Abadie, Thierry Levade, Céline Colacios, Bruno Ségui, Nicolas Meyer
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 1037–1047.
https://doi.org/10.1158/1078-0432.CCR-20-3449
Published: 15 February 2021
View article titled, Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Open the PDF for Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, Valerie Cristina, Edith Borcoman, Eric Deutsch, Rastislav Bahleda, Valentin Calugaru, Anouchka Modesto, Elisabeth Rouits, Kathrin Gollmer, Gregoire Vuagniaux, Philippa Crompton, Claudio Zanna, Sergio Szyldergemajn, Jean-Pierre Delord, Jean Bourhis
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6429–6436.
https://doi.org/10.1158/1078-0432.CCR-20-0425
Published: 15 December 2020
View article titled, Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, Enrique Grande, Jean-Pierre Delord, Ronnie Shapira-Frommer, Emily Bergsland, Manisha Shah, Marwan Fakih, Shunji Takahashi, Sarina A. Piha-Paul, Bert O'Neil, Sajeve Thomas, Martijn P. Lolkema, Menghui Chen, Nageatte Ibrahim, Kevin Norwood, Julien Hadoux
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2124–2130.
https://doi.org/10.1158/1078-0432.CCR-19-3014
Published: 01 May 2020
View article titled, Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Open the PDF for Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study in another window
Includes: Supplementary data
Journal Articles

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Hope S. Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A. Ott, Sarina A. Piha-Paul, Philippe L. Bedard, Jasgit Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andrea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2804–2811.
https://doi.org/10.1158/1078-0432.CCR-17-3452
Published: 14 June 2018
View article titled, Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Open the PDF for Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F. Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez-Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh-de Parseval, Tim Demuth, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5339–5348.
https://doi.org/10.1158/1078-0432.CCR-16-2923
Published: 15 September 2017
View article titled, Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma
Open the PDF for Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Fabian Birzele, Edgar Voss, Adam Nopora, Konrad Honold, Florian Heil, Sabine Lohmann, Henk Verheul, Christophe Le Tourneau, Jean-Pierre Delord, Carla van Herpen, Devalingam Mahalingam, Andrew L. Coveler, Valerie Meresse, Stefan Weigand, Valeria Runza, Michael Cannarile
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (12): 2753–2762.
https://doi.org/10.1158/1078-0432.CCR-14-2141
Published: 14 June 2015
View article titled, CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Open the PDF for CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children

Melanie White-Koning, Elodie Civade, Birgit Geoerger, Fabienne Thomas, Marie-Cécile Le Deley, Isabelle Hennebelle, Jean-Pierre Delord, Etienne Chatelut, Gilles Vassal
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4862–4871.
https://doi.org/10.1158/1078-0432.CCR-10-3278
Published: 17 July 2011
View article titled, Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children
Open the PDF for Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children in another window
Journal Articles

Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer

Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, Ben C. Allal
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (17): 4434–4445.
https://doi.org/10.1158/1078-0432.CCR-09-2795
Published: 31 August 2010
View article titled, Preclinical and Clinical Evidence that Deoxy-2-[<sup>18</sup>F]fluoro-<sc>D</sc>-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
Open the PDF for Preclinical and Clinical Evidence that Deoxy-2-[<sup>18</sup>F]fluoro-<sc>D</sc>-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Vinflunine: A New Microtubule Inhibitor Agent

Jaafar Bennouna, Jean-Pierre Delord, Mario Campone, Laurent Nguyen
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (6): 1625–1632.
https://doi.org/10.1158/1078-0432.CCR-07-2219
Published: 17 March 2008
View article titled, Vinflunine: A New Microtubule Inhibitor Agent
Open the PDF for Vinflunine: A New Microtubule Inhibitor Agent in another window
Journal Articles

Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma

Fabienne Thomas, Philippe Rochaix, Adil Benlyazid, Jérôme Sarini, Michel Rives, Jean Louis Lefebvre, Ben C. Allal, Frédéric Courbon, Etienne Chatelut, Jean-Pierre Delord
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7086–7092.
https://doi.org/10.1158/1078-0432.CCR-07-1370
Published: 03 December 2007
View article titled, Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma
Open the PDF for Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma in another window
Journal Articles

Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine

Antje Hoppe, Sophie Séronie-Vivien, Fabienne Thomas, Jean-Pierre Delord, Laurence Malard, Pierre Canal, Etienne Chatelut
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 3038–3044.
https://doi.org/10.1158/1078-0432.CCR-04-2086
Published: 18 April 2005
View article titled, Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine
Open the PDF for Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine in another window